Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Lilly Rejected by U.S. Supreme Court in Gemzar Patent Case

The U.S. Supreme Court refused to consider Eli Lilly & Co.’s bid to re-establish the drugmaker’s exclusive right to sell the cancer medicine Gemzar.

The justices today left intact a federal appeals court decision invalidating a patent that would have protected Gemzar from generic competition in the U.S. until May 2013.

Hospira Inc. and Teva Pharmaceutical Industries Ltd. began selling generic versions after the lower court ruling. Had the Supreme Court intervened and backed Lilly, those two companies might have had to pay damages and pull their products from the market.

Gemzar, whose chemical name is gemcitabine, generated U.S. sales of $723 million for Indianapolis-based Lilly last year, with generic competition beginning Nov. 15. The drug is used for lung, breast, pancreatic and ovarian cancers.

The appeals court ruling was a victory for India’s Sun Pharmaceutical Industries Ltd., a generic-drug manufacturer that challenged the Lilly patent. Trade groups representing brand-name drug and biotechnology companies joined Lilly in urging Supreme Court review.

Lilly is also waging a separate patent fight with Hospira at the U.S. International Trade Commission.

The case is Eli Lilly v. Sun Pharmaceutical, 10-972.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.